Aganirsen

阿加尼生

Report date: 2026/02/02 20:01:46
NME

Base Information

Drug NameAganirsen
Drug Alias NameAntisense oligonucleotide TATCCGGAGGGCTCGCCATGCTGCTGS-101TATCCGGAGGGCTCGCCATGCTGCT
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionInsulin receptor substrate 1 blockers
TargetsInsulin receptor substrate 1
Therapy Area/IndicationsDiabetic macular oedemaKeratoplasty rejectionRetinal Vein Occlusion +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGene Signal
China Registration ClassN/A

Develop Information

Active CompaniesGene Signal
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaKeratoplasty rejectionWet age-related macular degeneration +[4] 
Inactive IndicationsRetinal Vein OcclusionGlaucoma, Neovascular

Other Information

ATC CodeN/A
Related LinksN/A